©istock.com/Andrea Obzerova
Interdisciplinary CompetenceMolecular Diagnostics
Know how in the analysis of genetic material.
For the benefit of patients.

IllnessHypogonadism, hypogonadotropic; differential diagnosis

Summary

Short information

Comprehensive differential diagnostic panel for Hypogonadism, hypogonadotropic comprising 14 or altogether 62 curated genes according to the clinical signs

ID
HP0220
Number of genes
55 Accredited laboratory test
Examined sequence length
25,3 kb (Core-/Core-canditate-Genes)
100,2 kb (Extended panel: incl. additional genes)
Analysis Duration
on request
Test material
  • EDTA-anticoagulated blood (3-5 ml)
Diagnostic indications

NGS +

[Sanger]

 

Gene panel

Selected genes

NameExon Length (bp)OMIM-GReferenz-Seq.Heredity
ANOS12043NM_000216.4XLR
CHD78994NM_017780.4AD
FEZF11428NM_001024613.4AR
FGF8735NM_033163.5AD, AR
FGFR12469NM_023110.3AR
GNRH1291NM_000825.3AR
GNRHR987NM_000406.3AR
IL17RD2220NM_017563.5AR
KISS1R1197NM_032551.5AR
NSMF1587NM_015537.5AR
PROK2390NM_001126128.2AR, Oligo, AD
PROKR21155NM_144773.4AR
TAC3366NM_013251.4AR
TACR31398NM_001059.3AR
CLPP834NM_006012.4AR
CPE1431NM_001873.4AR
CUL4B2742NM_003588.4XLR
DCAF171563NM_025000.4AR
DUSP61146NM_001946.4AD
FGF17651NM_003867.4AD
FLRT31950NM_198391.3AD
FSHB390NM_000510.4AR
GLI24761NM_005270.5AD
HAMP255NM_021175.4AR
HESX1558NM_003865.3AD, AR
HFE1047NM_000410.4AR
HS6ST11236NM_004807.3AD
KISS1417NM_002256.4AR
KLB3135NM_175737.4AD
LEP504NM_000230.3AR
LEPR3498NM_002303.6AR
LHB426NM_000894.3AR
LHX31209NM_014564.5AR
LHX41173NM_033343.4AD
NR0B11413NM_000475.5XLR
PCSK12262NM_000439.5AR
PNPLA63984NM_006702.5AR
POLR3A4173NM_007055.4AR
POLR3B3402NM_018082.6AR
POU1F1876NM_000306.4AR, AD
PROP1681NM_006261.5AR
RAB3GAP12946NM_012233.3AR
RAB3GAP24182NM_012414.4AR
RNF2162772NM_207111.4AR
SEMA3A2316NM_006080.3AD
SLC29A31428NM_018344.6AR
SLC40A11716NM_014585.6AD
SOX101401NM_006941.4AD
SOX2954NM_003106.4AD
SPRY4969NM_030964.5AD
STUB1912NM_005861.4AD, AR
TCF122121NM_207036.2AD
TFR22406NM_003227.4AR
TUBB31353NM_006086.4AR
WDR113675NM_018117.12AD

Informations about the disease

Clinical Comment

Hypogonadotropic hypogonadism (HH) is either due to low concentrations of sexual steroids (oestrogen, progesterone) or gonadotropins (FSH, LH) with hypothalamic or pituitary causes. The majority of cases is diagnosed in men; women usually have primary amenorrhoea, which is often not genetic. HH can occur congenitally or later, and is usually diagnosed definitively at the age of 18 years. The detection rate is significantly higher in congenital HH (35-60%) than in late puberty as an expression of later manifested forms of HH that cannot be clinically distinguished. Statements on penetrance rates and expressivity must be made on the basis of genes or mutations. An inconspicuous genetic finding certainly does not mean that the suspected clinical diagnosis is excluded.

Reference: https://www.nature.com/articles/nrendo.2015.112

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520594/

 

Synonyms
  • Allelic: CHARGE syndrome (CHD7)
  • Allelic: Encephalocraniocutaneous lipomatosis, somatic mosaic (FGFR1)
  • Allelic: Encephalocraniocutaneous lipomatosis; Hartsfield syndrome; Jackson-Weiss syndrome (FGFR1)
  • Allelic: Fascioscapulohumeral muscular dystrophy 2, digenic (SMCHD1)
  • Allelic: Hartsfield syndrome (FGFR1)
  • Allelic: Holoprosencephaly 9 (GLI2)
  • Allelic: Jackson-Weiss syndrome (FGFR1)
  • Allelic: Laurence-Moon syndrome (PNPLA6)
  • Allelic: Microphthalmia, syndromic 3 (SOX2)
  • Allelic: Obesity, susceptibility to, BMIQ12 (PCSK1)
  • Allelic: Obesity, susceptibility to, BMIQ14 (FTO)
  • Allelic: Oliver-McFarlane syndrome (PNPLA6)
  • Allelic: Osteoglophonic dysplasia (FGFR1)
  • Allelic: Osteoglophonic dysplasia; Pfeiffer syndrome; Trigonocephaly 1 (FGFR1)
  • Allelic: PCWH syndrome (SOX10)
  • Allelic: Pfeiffer syndrome (FGFR1)
  • Allelic: Precocious puberty, central, 1 (KISS1R)
  • Allelic: Septooptic dysplasia (HESX1)
  • Allelic: Spastic paraplegia 39, AR (PNPLA6)
  • Allelic: Treacher Collins syndrome 3 (POLRR1C)
  • Allelic: Trigonocephaly 1 (FGFR1)
  • Allelic: Wiedemann-Rautenstrauch syndrome (POLR3A)
  • 46XY sex reversal 2, dosage-sensitive (NR0B1)
  • Adrenal hypoplasia, congenital (NR0B1)
  • Allelic: Blood group, John-Milton-Hagen system (SEMA7A)
  • Allelic: Luteinizing hormone resistance, female (LHCGR)
  • Allelic: Precocious puberty, male (LHCGR)
  • Alopecia, neurologic defects + endocrinopathy syndrome (RBM28)
  • Bardet-Biedl syndrome genes (Rp, obesity, kidney dysfunction, hypogonadism...)
  • Bosma arhinia microphthalmia syndrome (SMCHD1)
  • Boucher-Neuhauser syndrome (PNPLA6)
  • CHARGE syndrome (SEMA3E)
  • Cerebellar ataxia + hypogonadotropic hypogonadism (RNF216)
  • Congenital hypogonadotropic hypogonadism (KLB)
  • Congenital hypogonadotropic hypogonadism [MONDO:0015770] (CCDC141)
  • Craniosynostosis 3 (TCF12)
  • Culler-Jones syndrome (GLI2)
  • Fibrosis of extraocular muscles, congenital, 3A (TUBB3)
  • Growth hormone deficiency with pituitary anomalies (HESX1)
  • Growth retardation, developmental delay, facial dysmorphism (FTO)
  • Hemochromatosis (HFE)
  • Hemochromatosis, type 2B (HAMP)
  • Hemochromatosis, type 3 (TFR2)
  • Hemochromatosis, type 4 (SLC40A1)
  • Histiocytosis-lymphadenopathy plus syndrome (SLC29A3)
  • Hypogonadotropic hypogonadism 1 with/-out anosmia; Kallmann syndrome 1 (ANOS1)
  • Hypogonadotropic hypogonadism 10 with/-out anosmia (TAC3)
  • Hypogonadotropic hypogonadism 11 with/-out anosmia (TACR3)
  • Hypogonadotropic hypogonadism 12 with/-out anosmia (GNRH1)
  • Hypogonadotropic hypogonadism 13 with/-out anosmia (KISS1)
  • Hypogonadotropic hypogonadism 14 with/-out anosmia (WDR11)
  • Hypogonadotropic hypogonadism 15 with/-out anosmia (HS6ST1)
  • Hypogonadotropic hypogonadism 16 with/-out anosmia (SEMA3A)
  • Hypogonadotropic hypogonadism 17 with/-out anosmia (SPRY4)
  • Hypogonadotropic hypogonadism 18 with/-out anosmia (IL17RD)
  • Hypogonadotropic hypogonadism 19 with/_out anosmia (DUSP6)
  • Hypogonadotropic hypogonadism 2 with/-out anosmia (FGFR1)
  • Hypogonadotropic hypogonadism 20 with/-out anosmia (FGF17)
  • Hypogonadotropic hypogonadism 21 with anosmia (FLRT3)
  • Hypogonadotropic hypogonadism 22, with/-out anosmia (FEZF1)
  • Hypogonadotropic hypogonadism 23 with/-out anosmia (LHB)
  • Hypogonadotropic hypogonadism 24 without anosmia (FSHB)
  • Hypogonadotropic hypogonadism 25 with anosmia (NDNF)
  • Hypogonadotropic hypogonadism 3 with/-out anosmia (PROKR2)
  • Hypogonadotropic hypogonadism 4 with/-out anosmia (PROK2)
  • Hypogonadotropic hypogonadism 5 with/-out anosmia (CHD7)
  • Hypogonadotropic hypogonadism 6 with/-out anosmia (FGF8)
  • Hypogonadotropic hypogonadism 7 without anosmia (GNRHR)
  • Hypogonadotropic hypogonadism 8 with/-out anosmia (KISS1R)
  • Hypogonadotropic hypogonadism 9 with/_out anosmia (NSMF)
  • Hypogonadotropic hypogonadism [MONDO:0018555] (SEMA3F)
  • Hypogonadotropic hypogonadism without anosmia; normosmic IHH [panelapp] (CCDC141)
  • Hypogonadotropic hypogonadism, delayed puberty, primary ovary insufficiency [panelapp] (IGSF10)
  • Intellectual developmental disorder + hypogonadotropic hypogonadism (CPE)
  • Isolated GnRH deficiency [genereviews] (AXL)
  • Isolated GnRH deficiency [genereviews] (SRA1)
  • Leukodystrophy, hypomyelinating, 11 (POLR1C)
  • Leukodystrophy, hypomyelinating, 7, with/-out oligodontia and/or hypogon. hypogonadism (POLR3A)
  • Leukodystrophy, hypomyelinating, 8, with/-out oligodontia and/or hypogon. hypogonadism (POL3RB)
  • Leydig cell hypoplasia with hypergonadotropic hypogonadism (LHCGR)
  • Martsolf syndrome 1 (RAB3GAP2)
  • Martsolf syndrome 2 (RAB3GAB1)
  • Mental retardation, XL, syndromic 15 [Cabezas type] (CUL4B)
  • Obesity with impaired prohormone processing (PCSK1)
  • Obesity, morbid, due to leptin deficiency (LEP)
  • Obesity, morbid, due to leptin receptor deficiency (LEPR)
  • Optic nerve hypoplasia + abnormalities of the central nervous system (SOX2)
  • PCWH syndrome (SOX10)
  • Perrault syndrome 3 (CLPP)
  • Pituitary hormone deficiency, combined, 1 (POUF1)
  • Pituitary hormone deficiency, combined, 2 (PROP1)
  • Pituitary hormone deficiency, combined, 3 (LHX3)
  • Pituitary hormone deficiency, combined, 4 (LHX4)
  • Pituitary hormone deficiency, combined, 5 (HESX1)
  • Prader-Willi syndrome (NDN, SIM1, SNRPN)
  • Spinocerebellar ataxia, AR 16 (STUB1)
  • Waardenburg syndrome, type 2E, with/-out neurologic involvement (SOX10)
  • Waardenburg syndrome, type 4C (SOX10)
  • Warburg micro syndrome 1 (RAB3GAP1)
  • Warburg micro syndrome 2 (RAB3GAP2)
  • Woodhouse-Sakati syndrome (DCAF17)
Heredity, heredity patterns etc.
  • AD
  • AR
  • Oligo
  • XLR
OMIM-Ps
  • Multiple OMIM-Ps
ICD10 Code

Bioinformatics and clinical interpretation

Test-Stärken

  • DAkkS-akkreditiertes Labor
  • EU-Richtlinie für IVD in Umsetzung
  • Qualitäts-kontrolliert arbeitendes Personal
  • Leistungsstarke Sequenzierungstechnologien, fortschrittliche Target-Anreicherungsmethoden und Präzisions-Bioinformatik-Pipelines sorgen für überragende analytische Leistung
  • Sorgfältige Kuratierung klinisch relevanter und wissenschaftlich begründeter Gen-Panels
  • eine Vielzahl nicht Protein-kodierender Varianten, die in unseren klinischen NGS-Tests mit erfasst werden
  • unser strenges Variantenklassifizierungsschema nach ACMG-Kriterien
  • unser systematischer klinischer Interpretations-Workflow mit proprietärer Software ermöglicht die genaue und nachvollziehbare Verarbeitung von NGS-Daten
  • unsere umfassenden klinischen Aussagen

Testeinschränkungen

  • Gene mit eingeschränkter Abdeckung werden gekennzeichnet
  • Gene mit kompletten oder partiellen Duplikationen werden gekennzeichnet
  • es wird angenommen, dass ein Gen suboptimal abgedeckt ist, wenn >90% der Nukleotide des Gens bei einem Mapping-Qualitätsfaktor von >20 (MQ>20) nicht abgedeckt sind
  • die Sensitivität der Diagnostik zur Erkennung von Varianten mit genannten Testeinschränkungen ist möglicherweise begrenzt bei:
  • Gen-Konversionen
  • komplexe Inversionen
  • Balancierte Translokationen
  • Mitochondriale Varianten
  • Repeat-Expansionen, sofern nicht anders dokumentiert
  • nicht kodierende Varianten, die Krankheiten verursachen, die von diesem Panel nicht mit abgedeckt werden
  • niedriger Mosaik-Status
  • Repeat-Blöcke von Mononukleotiden
  • Indels >50bp (Insertionen-Deletionen)
  • Deletionen oder Duplikationen einzelner Exons
  • Varianten innerhalb von Pseudogenen
  • die analytische Sensitivität kann geringer ausfallen werden, wenn die DNA nicht von amedes genetics extrahiert wurde

Laboratory requirement

  • Die in grün gezeigten Gene sind kuratiert und werden als Gen-Panel untersucht. Eine Erweiterung des Panels (blau gezeigte Gene, jeweils ebenfalls kuratiert) kann auf Anfrage erfolgen. Sofern unter "Erweitertes Panel" ein Minuszeichen angezeigt wird, sind nur Core-/Basis-Gene verfügbar.

  • Für die Anforderung einer genetischen Untersuchung senden Sie uns bitte die Krankheits-ID auf einem Überweisungsschein. Bitte die Material-Angabe beachten.

  • Für privat versicherte Patienten empfehlen wir einen Antrag auf Kostenübernahme bei der Krankenversicherung.

  • Die Untersuchung wird auch für Selbstzahler angeboten.